7,081 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 7,081 shares of the medical research company's stock, valued at approximately $1,846,000.

Several other institutional investors have also recently made changes to their positions in AMGN. Van ECK Associates Corp grew its stake in shares of Amgen by 263.8% in the 4th quarter. Van ECK Associates Corp now owns 1,038,593 shares of the medical research company's stock worth $270,699,000 after acquiring an additional 753,147 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Amgen by 40.7% in the 4th quarter. Nordea Investment Management AB now owns 2,338,665 shares of the medical research company's stock worth $609,526,000 after acquiring an additional 676,598 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Amgen by 11.7% in the 3rd quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company's stock worth $1,657,183,000 after buying an additional 538,545 shares during the last quarter. Proficio Capital Partners LLC boosted its holdings in shares of Amgen by 35,087.4% in the 4th quarter. Proficio Capital Partners LLC now owns 470,808 shares of the medical research company's stock worth $122,711,000 after buying an additional 469,470 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Amgen by 1.2% in the 3rd quarter. State Street Corp now owns 29,317,018 shares of the medical research company's stock worth $9,446,236,000 after buying an additional 345,537 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Insider Buying and Selling at Amgen

In other news, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 over the last ninety days. Insiders own 0.69% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on AMGN shares. Wolfe Research started coverage on shares of Amgen in a report on Friday, November 15th. They issued a "peer perform" rating on the stock. UBS Group reissued a "hold" rating on shares of Amgen in a report on Wednesday, February 12th. Jefferies Financial Group reissued a "buy" rating and issued a $380.00 price target on shares of Amgen in a report on Tuesday, November 12th. StockNews.com downgraded shares of Amgen from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Finally, Citigroup reissued a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $314.09.

Amgen Price Performance

NASDAQ AMGN traded up $1.41 on Tuesday, reaching $312.19. 3,819,193 shares of the company's stock traded hands, compared to its average volume of 2,545,991. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock has a 50-day simple moving average of $282.76 and a 200 day simple moving average of $299.66. The stock has a market cap of $167.71 billion, a PE ratio of 41.35, a P/E/G ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.05%. Amgen's payout ratio is currently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.